Drug Policy Archives - Page 3 of 52 - Reason Foundation

Model legislation for optimal state regulation of hemp cannabinoids

Commentary by Michelle Minton and Geoffrey Lawrence

DEA’s increased DMT quota signals positive advancement in psychedelic research

Commentary by Madison Carlino

Rethinking the need for double-blind placebo trials in psychedelic clinical investigations

Commentary by Madison Carlino

Psychedelic treatment for neurodegenerative disorders

Policy Brief by Madison Carlino

Psychedelic therapy offers possible new hope for Alzheimer’s disease sufferers

Commentary by Madison Carlino

Nonconsensual drug testing raises serious ethical concerns

Commentary by Layal Bou Harfouch

Harm reduction recommendations for the Trump administration

Commentary by Layal Bou Harfouch

Intoxicating hemp products in Ohio need regulation, not prohibition

Commentary by Michelle Minton

Batch-tracking: The next wave of marijuana tracking systems

Commentary by Madison Carlino and Geoffrey Lawrence

More Drug Policy

Prev
1
2
3
4
5
6
7
...
52
Next